drugset / Trial / NCT02705638
Treatment of IgG4-Related Disease With Revlimid and Rituximab
NaSingle-groupOpen-labelTreatment
Summary
Among persons with Immunoglobulin G subclass 4 Related Disease (IgG4)-related disease who have persistent or recurrent disease despite standard therapies, does combination therapy with rituximab and revlimid cause a sustained disease remission?
Timeline
- Start
- 2016-04
- Primary completion
- 2019-04
- Completion
- 2019-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 20 mg | Oral |
| Subject | Rituximab | Monoclonal antibody | 1000 mg | Intravenous |